KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other Accumulated Expenses (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Other Accumulated Expenses for 11 consecutive years, with $23.4 million as the latest value for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses rose 4.87% year-over-year to $23.4 million; the TTM value through Mar 2026 reached $23.4 million, up 4.87%, while the annual FY2025 figure was $22.7 million, 16.83% up from the prior year.
  • Other Accumulated Expenses hit $23.4 million in Q1 2026 for Ionis Pharmaceuticals, up from $22.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $23.4 million in Q1 2026 and bottomed at $7.5 million in Q4 2022.
  • Average Other Accumulated Expenses over 5 years is $15.9 million, with a median of $17.1 million recorded in 2024.
  • Year-over-year, Other Accumulated Expenses crashed 38.81% in 2022 and then skyrocketed 123.31% in 2025.
  • Ionis Pharmaceuticals' Other Accumulated Expenses stood at $7.5 million in 2022, then grew by 17.2% to $8.8 million in 2023, then skyrocketed by 120.38% to $19.5 million in 2024, then rose by 16.83% to $22.7 million in 2025, then grew by 2.87% to $23.4 million in 2026.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $23.4 million, $22.7 million, and $21.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.